GMAB Genmab AS

$30.26

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/16/2025

About Genmab AS

Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.

Website: https://www.genmab.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1434265
Address
TOLDBODGADE 33, 1253 COPENHAGEN K, DK
Valuation
Market Cap
$12.54B
P/E Ratio
10.89
PEG Ratio
1.06
Price to Book
2.26
Performance
EPS
$1.84
Dividend Yield
—
Profit Margin
36.40%
ROE
23.00%
Technicals
50D MA
$20.50
200D MA
$22.98
52W High
$30.41
52W Low
$17.23
Fundamentals
Shares Outstanding
626M
Target Price
$29.38
Beta
0.96

GMAB EPS Estimates vs Actual

● Estimated
● Actual

GMAB News & Sentiment

Nov 10, 2025 • Benzinga SOMEWHAT-BULLISH
Zscaler To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Monday - Genmab ( NASDAQ:GMAB ) , HubSpot ( NYSE:HUBS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler cut SITE Centers Corp. ( NYSE:SITE ) price target from $12 to $10.
Nov 07, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Research Update
Scancell Holdings ...
Nov 06, 2025 • GlobeNewswire NEUTRAL
Genmab Announces Financial Results for the Nine Months of 2025
November 6, 2025 Copenhagen, Denmark. Interim Report for the Nine Months Ended September ...
Nov 03, 2025 • GlobeNewswire NEUTRAL
BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
BioNTech SE today reported financial results for the three and nine months ended September 30, 2025 and provide an update on its corporate progress.
Oct 31, 2025 • Zacks Commentary NEUTRAL
AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised
ABBV tops Q3 earnings and revenue estimates, driven by Rinvoq and Skyrizi gains, and lifts its 2025 EPS outlook.
Oct 28, 2025 • GlobeNewswire NEUTRAL
BioNTech to Host Innovation Series R&D Day on November 11, 2025
MAINZ, Germany, October 28, 2025 ( GLOBE NEWSWIRE ) -- BioNTech SE ( Nasdaq: BNTX, "BioNTech" or "the Company" ) , will host an edition of the Company's Innovation Series R&D Day at 09:00 a.m. Eastern Standard Time ( 3:00 p.m. CET ) on Tuesday, November 11, 2025 in New York City, U.S.
Sentiment Snapshot

Average Sentiment Score:

0.222
50 articles with scored sentiment

Overall Sentiment:

Bullish

GMAB Reported Earnings

Aug 07, 2025
Jun 30, 2025 (Post market)
0.2 Surprise
  • Reported EPS: $0.54
  • Estimate: $0.34
  • Whisper: —
  • Surprise %: 58.8%
May 08, 2025
Mar 31, 2025 (Post market)
0.08 Surprise
  • Reported EPS: $0.31
  • Estimate: $0.23
  • Whisper: —
  • Surprise %: 34.8%
Feb 12, 2025
Dec 31, 2024 (Post market)
0.56 Surprise
  • Reported EPS: $0.84
  • Estimate: $0.28
  • Whisper: —
  • Surprise %: 200.0%
Nov 06, 2024
Sep 30, 2024 (Post market)
-0.04 Surprise
  • Reported EPS: $0.29
  • Estimate: $0.33
  • Whisper: —
  • Surprise %: -12.1%
Aug 08, 2024
Jun 30, 2024 (Post market)
0.0 Surprise
  • Reported EPS: $0.32
  • Estimate: $0.32
  • Whisper: —
  • Surprise %: 0.0%
May 02, 2024
Mar 31, 2024 (Post market)
0.15 Surprise
  • Reported EPS: $0.29
  • Estimate: $0.14
  • Whisper: —
  • Surprise %: 107.1%
Feb 14, 2024
Dec 31, 2023 (Post market)
-0.16 Surprise
  • Reported EPS: $0.14
  • Estimate: $0.30
  • Whisper: —
  • Surprise %: -53.3%
Nov 07, 2023
Sep 30, 2023 (Post market)
0.15 Surprise
  • Reported EPS: $0.46
  • Estimate: $0.31
  • Whisper: —
  • Surprise %: 48.4%
Aug 03, 2023
Jun 30, 2023 (Post market)
0.01 Surprise
  • Reported EPS: $0.30
  • Estimate: $0.29
  • Whisper: —
  • Surprise %: 3.5%

Financials